Five things for pharma marketers to know: Friday, October 24

Five things for pharma marketers to know: Friday, October 24

Ebola comes to NY; AstraZeneca drops antibiotics; FDA approves hemophilia A drug.

Lilly sales fall, drugmaker to keep rep count low

Lilly sales fall, drugmaker to keep rep count low

Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.

Claims show BMS's Abilify remains strong

The antipsychotic's hold on the market has been steady, despite generics of drugs such as AstraZeneca's Seroquel.

App may diagnose glaucoma

Researchers say the iPad app could help assess vision loss.

Five things for pharma marketers to know: Thursday, October 23

Five things for pharma marketers to know: Thursday, October 23

FDA panel endorses Novartis psoriasis drug; court rules with Pfizer on cancer drug patent; drugmakers may look for indemnity against losses from Ebola vaccines.

Biogen's strong quarter eclipsed by patient death

Biogen's strong quarter eclipsed by patient death

Despite strong performance by its MS therapies, the drugmaker's robust third-quarter sales were overshadowed by the death of a patient taking Tecfidera.The patient had a rare brain infection.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Actavis, Sanofi reportedly spar for Omega

Bloomberg reports that the race to merge with Omega also includes privately-held Boehringer Ingelheim and Perrigo.

Senate hearing may be on horizon for HCV drug prices

Sen. Bernard Sanders (I-VT) could hold a hearing after midterm elections to discuss the impact of costly new HCV treatments on the US Department of Veterans' Affairs.

Study hints at how brands should reach Millennials

Study hints at how brands should reach Millennials

The Post X-er, Post-Boomer generation considers traditional healthcare "sick care."

Five things for pharma marketers to know: Tuesday, October 21

Five things for pharma marketers to know: Tuesday, October 21

Shire bows out of AbbVie acquisition; CVS's PBM will charge premium for consumers who fill scripts at tobacco-selling pharmacies; Reckitt Beckinser will rebrand following demerger.

Crohn's drug shows promise in mid-stage trial

Crohn's drug shows promise in mid-stage trial

Preliminary Phase-II data suggest remission rates among patients taking the drug were significantly better than those for subjects on current treatments.

Takeda's Contrave hits pharmacy shelves

Takeda's Contrave hits pharmacy shelves

Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.

Valeant-Allergan duel continues

Valeant indicated in its third-quarter earnings call that it expects to increase its bid for Allergan.

Five things for pharma marketers to know: Friday, October 17

Five things for pharma marketers to know: Friday, October 17

Amgen sues Sanofi and Regeneron over PCSK9 patents; FDA panel wants Chantix black box to stay; Valeant-Allergan uproar rises in pitch; Pharmacyclics and Roche team up against CLL; and GSK's Ebola vax may "miss" the current crisis.

AbbVie-free Shire could open new opportunities

AbbVie-free Shire could open new opportunities

AbbVie's board is encouraging shareholders to kill the Shire acquisition, and analysts say a breakup would still leave Shire in a strong position.

Panel seems to like Novartis drug

Pre-review documents indicate a favorable opinion of the IL-17 inhibitor secukinumab.

New FDA division launches Jan. 1

Resignations stymied the Office of Pharmaceutical Quality's beginning.

Five things for pharma marketers to know: Thursday, October 16

Five things for pharma marketers to know: Thursday, October 16

AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung disease.

AbbVie reconsiders Shire

AbbVie reconsiders Shire

AbbVie is thinking about modifying or walking away from its offer to buy Dublin's Shire. A breakup would cost the Illinois company over $1.6 billion.

J&J offers government payer hep. C guarantee

The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.

New exclusivity rules confound

A draft guidance publication date determines whether drugmakers get three or five years of market exclusivity.

Cosmo moves to Ireland

Jilted Salix acquisition target Cosmo Pharmaceutical is headed for the Emerald Isle.

Five things for pharma marketers to know: Wednesday, October 15

Five things for pharma marketers to know: Wednesday, October 15

AbbVie's board to reconsider Shire move; docs warm up to ACA; Eisai orphan thyroid cancer drug receives Priority Review.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Pfizer gets palbo review date

Pfizer gets palbo review date

The FDA will vote for or against the breast cancer drug by April 13, 2015.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

New Ireland tax rule does not fluster pharma

Ireland plans on closing off a tax advantage but pharma does not appear to flinch.

Five things for pharma marketers to know: Tuesday, October 14

Five things for pharma marketers to know: Tuesday, October 14

BMS, Janssen and Pharmacyclics to test Opdivo/Imbruvica pairing; Google's latest health experiment will connect docs and patients over video-conferencing Hangouts tool; Five Ranbaxy execs resign after generics firm was acquired by Sun.

FDA approves Sovaldi HCV combo

FDA approves Sovaldi HCV combo

The sofosbuvir-ledipasvir combo is expected to run the average genotype 1 patient $80,000.

Specialty prescription costs hurt across the board

Specialty prescription costs hurt across the board

Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.

Shire delays ADD medication submission

The company is working with the FDA on new clinical trial requirements.

Five things for pharma marketers to know: Thursday, October 9

Five things for pharma marketers to know: Thursday, October 9

Endo to acquire Auxilium for an estimated $2.6bn; Novartis says good-bye to three execs; NIH opens wallet for rare disease research; CMS's Open Payments show financial disparity between men and women; Clarient and GSK collaborate in cancer testing.

Amgen releases Humira biosimilar data

The company says ABP 510 hit its primary endpoint in an adalimumab comparison.

Researchers link prescriptions and time of day

In short: more antibotic prescriptions are written in the afternoon than in the morning.

Task Force endorses T2D screening

The US Preventive Services Task Force wants adults at risk for type 2 diabetes to get tested.

Cardiology groups endorse AZ's Brilinta over Plavix

Two cardiology associations advise prescribing Brilinta over Plavix for management of acute chest pain without electrocardiogram changes.

Teva narrows focus, trims R&D

Teva narrows focus, trims R&D

The drugmaker is poised to cut 14 pipeline projects loose.

Nearly half of consumers wary of healthcare costs, insurer finds

Nearly half of consumers wary of healthcare costs, insurer finds

Cigna said found paying for medications and hospitalizations were top healthcare concerns.

Hospital backlash begins after Genentech imposes change

Genentech's decision to pare access to three breast cancer drugs has spurred hospitals to take action.

Analysts see potential in Novartis's serelaxin

Analysts see potential in Novartis's serelaxin

Two regulatory agencies have rejected the drug, but analysts indicate the pipeline acute heart failure treatment could have limited market success.

Becton Dickinson buys CareFusion

An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.

Five things for pharma marketers to know: Monday, October 6

Five things for pharma marketers to know: Monday, October 6

Novartis BMS collaboration to evaluate Opdivo paired with three lung cancer treatments; Forbes weighs in on 60 Minutes segment; Sanofi management disagreements delay established drug portfolio sale; FDA sets price for Rare Pediatric Disease Priority Review vouchers; the GPhA challenges lawmakers' misconceptions of generic drug prices.

Five things for pharma marketers to know: Friday, October 3

Five things for pharma marketers to know: Friday, October 3

Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep

Lilly drops lupus drug from trials

Lilly drops lupus drug from trials

Eli Lilly said it discontinued tabalumab, a drug being tested in Phase-III trials for lupus, after it failed to outperform the standard of care.

Five things for pharma marketers to know: Thursday, October 2

Five things for pharma marketers to know: Thursday, October 2

Government, charities spur production of Ebola treatment Zmapp; Venture capital likes digital health this year; Eli Lilly abandons lupus drug after disappointing Phase-III trial.

Sales rep restrictions point to need for a pharma rethink

Sales rep restrictions point to need for a pharma rethink

A survey shows sales rep bans are accelerating, while also pointing to a limited-time opportunity for pharma to become a significant partner for healthcare systems.

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Sucampo goes all-in on Amitiza with new DTC effort

Sucampo goes all-in on Amitiza with new DTC effort

The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.

Payers OK-ish with orphan drug prices

A survey shows fewer payers expect more restrictive policies in the near-term.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Five things for pharma marketers to know: Tuesday, September 30

Five things for pharma marketers to know: Tuesday, September 30

New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.

Pacira gets OPDP opioid promotion Warning Letter

Pacira gets OPDP opioid promotion Warning Letter

The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.

Consumers modify mobile health devices

Mobile health devices may be more than they appear to be—consumers are taking an open-source approach to getting the monitors they want.

Five things for Pharma Marketers to know: Monday, September 29

Five things for Pharma Marketers to know: Monday, September 29

Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.

Five things for pharma marketers to know: Friday, September 26

Five things for pharma marketers to know: Friday, September 26

US government looks for alternative, nondrug, pain relief options for veterans; Gilead's HCV combo scores positive opinion in EU; FDA reopens commentary for social media draft guidance.

Sanofi rolls out HCP software

Sanofi rolls out HCP software

MyStar Connect—available in Europe—translates glucose readings into actionable graphics.

Acorda's $525M Civitas buy opens Parkinson's pipeline

Acorda's $525M Civitas buy opens Parkinson's pipeline

The all-cash deal gives Acorda access to an experimental inhaled Parkinson's treatment that is meant to help patients when medication levels dip and symptoms surface.

NICE poised to turn down three ulcerative colitis drugs

Final guidance will float in around January, but the news puts Janssen and AbbVie on notice.

Advocates want FDA's Hamburg out

The reason: opioids.

Five things for pharma marketers to know: Wednesday, September 24

Five things for pharma marketers to know: Wednesday, September 24

Pfizer tries to acquire Actavis; PhRMA says FDA social media rules are bad for consumers; US diabetes rates begin to slow.

MedImmune gets Fast Track nod

The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action.

OIG: Crack down on Medicare co-pay cards

The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.

Lawmakers float generic drug legislation

The bill proposes fining branded drugmakers for not complying.

Auxilium turns down Endo, leaves door open

Auxilium turns down Endo, leaves door open

The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.

Five things for pharma marketers to know: Monday, September 22

Five things for pharma marketers to know: Monday, September 22

GSK releases polio-infected water into Lasne River in Belgium; House reps Burgess and Schwartz introduce CME exemption bill for Sunshine Act; NIH and FDA announce plan to create facebook-esque catalogue of oral-drugs.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

Missing generic hurts Rite Aid

The drugstore chain has lowered its forecast, and generics are just one reason.

Novartis NY layoffs coming

Plans to unwind the Suffern, NY, site move forward this winter.

Merck's weekly DPP-IV on par with daily Januvia: study

Merck's weekly DPP-IV on par with daily Januvia: study

Merck unveiled the DPP-IV clinical trial results at the European Association for the Study of Diabetes Annual meeting Thursday.

Endo makes $2.2B bid for Auxilium

Endo makes $2.2B bid for Auxilium

Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.

DOJ eyes Ranbaxy pricing

The Department of Justice is looking into Medicaid pricing.

Switzerland wants lower drug prices

Switzerland is pushing Roche to lower its prices on Perjeta

Five things for pharma marketers to know: Wednesday, September 17

HealthKit off to a bumpy start; Endo offers $2.2 billion for Auxilium; Gilead advanced pancreatic cancer drug fails in trial.

BMS striving to push Opdivo past Keytruda

BMS striving to push Opdivo past Keytruda

Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.

Merck osteoporosis drug does not wow

Merck osteoporosis drug does not wow

Analysts do not expect odanacatib to be a major earner.

Regeneron's Eylea scores Breakthrough label

The designation is for diabetic retinopathy for patients with diabetic macular edema.

AbbVie, Biogen to file MS drug next year

AbbVie, Biogen to file MS drug next year

Phase-III results of the AbbVie-Biogen Idec experimental multiple sclerosis shot Zinbryta (daclizumab) indicate the drug bests Avonex (interferon beta-1a) on some measures among relapse-remitting MS patients.

Takeda backs Contrave with 900 sales reps

Takeda backs Contrave with 900 sales reps

Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Xtandi duo boosts rep force for pre-chemo push

Xtandi duo boosts rep force for pre-chemo push

With its label extended to the pre-chemo setting, the prostate cancer drug is poised to reach a new group of urologists, and could upend J&J's Zytiga.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

BI Spiriva combo has Phase-III success

BI Spiriva combo has Phase-III success

The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."

Lilly basal bests Lantus in T1D, despite safety concerns

Lilly basal bests Lantus in T1D, despite safety concerns

Lilly's long-acting insulin showed it's more effective in type 1 diabetics than Lantus, but concerns about its overall profile persist.

FDA sanctions don't kill a business

Bloomberg reports that India's Wockhardt has become an M&A target.

Pfizer, Novartis ink respiratory deal

Pfizer will sell two Novartis drugs in the UK.

Roche to lay off 100, restructure

Sales reps are among the pinked-slipped in Spain.

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low on doc awareness

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Kyprolis fails to wow in survival trial

Kyprolis fails to wow in survival trial

Amgen now hopes a separate study will be enough to support the drug's advancement to a second-line therapy, but the lackluster results may impinge on its EU filing schedule.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.